SQUAWK/NEWS
Account
Account
Menu
Live NewsCategoriesequity

Sagimet Biosciences Inc. (SGMT) News

Track canonical SquawkNews coverage tagged to SGMT, Sagimet Biosciences Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 1 indexed stories across 1 publication days and is ordered by the same first-publication timeline used by LiveCast.

Symbol SGMT Asset equity Sector Markets 90 days 1 Last 9.54 Updated Aug 13, 2026, 11:01 AM UTC Open live news feed
H Sagimet Biosciences gets FDA “Study May Proceed” letter for Phase 3 Sagimet Biosciences (SGMT) says the FDA issued a “Study May Proceed” letter and IND clearance for a Phase 3 trial in acne in adolescent and adult patients. EQUITY | Aug 13, 2026, 11:01 AM UTC